said a two-year trial of the company's new cardiac devices showed that patients with heart failure had "marked improvement" in their ability to exercise and in their quality of life.
Medtronic's InSync resynchronization system will target patients who previously could only be treated with drugs or major surgery for heart failure.
Medtronic, a medical device maker, filed a premarket approval application with the
Food and Drug Administration
for the InSync system, which is deemed investigational in the U.S. but is commercially available in Europe.
Shares of Medtronic, which is based in Minneapolis, gained 76 cents, or 1.6%, to $47.48 in recent
New York Stock Exchange